You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Human Anti-Chimeric Antibodies (HACA)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Isolation of Human Recombinant Therapeutic Monoclonal

Recruiting
  • Pseudomonas Aeruginosa
  • Multi-antibiotic Resistance
  • Isolation of anti-Pseudomonas antibodies from type B lymphocytes
  • Grenoble, France
    Chu Grenoble Alpes
May 6, 2022

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,

Not yet recruiting
  • Idiopathic Inflammatory Myopathies
  • +3 more
  • (no location specified)
Nov 21, 2023

Nanoparticle for DSA Removal

Recruiting
  • Kidney Failure
  • Presence of Donor Specific Antibodies
    • Zurich, ZH, Switzerland
      University Hospital Zurich, Division of Anaesthesiology
    Mar 11, 2022

    Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

    Terminated
    Has Results
    • Lymphoma, B-Cell
    • +3 more
    • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 26, 2022

    Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T

    Recruiting
    • Non Hodgkin Lymphoma
    • +2 more
    • Fully human anti CD19 CAR-T Cell Dose
    • +2 more
    • Cleveland, Ohio
      University Hospitals Cleveland Medical Center, Case Comprehensiv
    Oct 4, 2022

    Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

    Completed
    Has Results
    • Kidney Cancer
    • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

    Not yet recruiting
    • Chronic Graft Versus Host Disease
    • +2 more
    • Biopsy
    • +11 more
    • Duarte, California
      City of Hope Medical Center
    Aug 7, 2023

    Ganglioneuroblastoma, High Risk Neuroblastoma Trial in Australia, New Zealand, United States (procedure, drug, biological,

    Active, not recruiting
    • Ganglioneuroblastoma
    • High Risk Neuroblastoma
    • Autologous Hematopoietic Stem Cell Transplantation
    • +14 more
    • Los Angeles, California
    • +9 more
    Sep 1, 2022

    Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

    Not yet recruiting
    • Refractory Non-Hodgkin Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • ARI0003
    • Santiago De Compostela, A Coruña, Spain
    • +6 more
    Oct 24, 2023

    Neuroblastoma Trial in Madison, Southampton, London (Nivolumab, Ch14.18/CHO)

    Recruiting
    • Neuroblastoma
    • Madison, Wisconsin
    • +2 more
    Mar 28, 2022

    Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Plasma Cell Leukemia
    • CAR-T (CAR-GPRC5D)
    • (no location specified)
    Feb 26, 2023

    Triple Negative Breast Cancer Trial in Saint-Herblain (89Zr-TLX250 PET/CT)

    Recruiting
    • Triple Negative Breast Cancer
    • 89Zr-TLX250 PET/CT
    • Saint-Herblain, France
      ICO René Gauducheau
    Oct 18, 2021

    Advanced Malignant Tumor Trial in Shanghai (Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant

    Recruiting
    • Advanced Malignant Tumor
    • Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
    • Shanghai, Shanghai, China
      Dragonboat Biopharmaceutical,Co.,Ltd
    Feb 3, 2021

    Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,

    Not yet recruiting
    • Metastatic Colorectal Carcinoma
    • +3 more
    • Bevacizumab
    • +11 more
    • (no location specified)
    May 9, 2023

    DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

    Terminated
    Has Results
    • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    • +5 more
    • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 1, 2022

    Immunoglobulins, Plasmapheresis and Rituximab in Lung

    Recruiting
    • Lung Transplantation
    • Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies
    • blood samples
    • Hannover, Germany
      Hannover Medical School, Department of Cardiothoracic, Transplan
    Aug 30, 2021

    Renal Cell Carcinoma (RCC) Trial in Heidelberg (Chimeric mAb cG250, Sunitinib malate)

    Terminated
    Has Results
    • Renal Cell Carcinoma (RCC)
    • Chimeric monoclonal antibody cG250
    • Sunitinib malate
    • Heidelberg, Victoria, Australia
      Austin Health (Ludwig Institute Oncology Unit)
    Oct 3, 2022

    Communicable Disease Transmission, Zoonotic Disease, Rabies Human Trial in Changchun City (recombinant anti-rabies human mAb

    Completed
    • Communicable Disease Transmission
    • +4 more
    • recombinant anti-rabies human monoclonal antibody injection (SYN023)
    • Rabies Vaccine
    • Changchun City, Jilin, China
      Jilin University
    Sep 23, 2021

    B-cell Non-Hodgkin's Lymphoma Trial (Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell

    Not yet recruiting
    • B-cell Non-Hodgkin's Lymphoma
    • Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
    • (no location specified)
    Oct 12, 2021

    Advanced Malignant Tumor, Castleman Disease, Digestive System Carcinoma Trial in Houston (biological, other, drug)

    Active, not recruiting
    • Advanced Malignant Neoplasm
    • +38 more
    • Bevacizumab
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 18, 2022

    Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck

    Active, not recruiting
    Has Results
    • Metastatic Head and Neck Squamous Cell Carcinoma
    • +2 more
    • Cetuximab
    • +2 more
    • Washington, District of Columbia
    • +1 more
    Mar 25, 2022

    Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

    Not yet recruiting
    • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
    • Polymorphic Post-Transplant Lymphoproliferative Disorder
    • Biopsy
    • +5 more
    • New Brunswick, New Jersey
    • +2 more
    Mar 23, 2023